Novel therapeutic approaches and a robust drug pipeline may provide hope for patients with Sjögren’s syndrome, according to a presenter at the 2021 Congress of Clinical Rheumatology-East.
“We are at a pretty exciting time for systemic Sjögren’s,” Nancy L. Carteron, MD, associate clinical professor of rheumatology at the University of California, San Francisco, said in her presentation.
That said, she was realistic about the amount of work that needs to be done for researchers and clinicians interested in this condition. “The Sjögren’s field is